BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

Exclusion Criteria

• •1. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
• •2. Active autoimmune diseases or history of autoimmune diseases that may relapse
• •3. Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
• •4. Participants with hepatitis B infection with HBV DNA ≥ 500 IU/mL (or ≥ 2500 copies/mL). Participants with active hepatitis C, and participants with HIV infection.
• •Note: Participants with chronic hepatitis B infection or resolved hepatitis B infection (HBV DNA \< 500 IU/mL or \< 2500 copies/mL) and considered stable are eligible. Participants with a negative HCV antibody test result at screening or a positive HCV antibody test result followed by a negative HCV RNA test result at screening are eligible to participate. Participants with treated HIV infection may be included if certain criteria are met.
• •5. History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including pulmonary fibrosis, or acute lung diseases.
• •6. Grade 3 immune-mediated adverse events on prior immune-oncology agent.
• •7. Cardiovascular risk factors, including but not limited to pulmonary embolism ≤ 28 days or history of acute myocardial infarction or heart failure ≤ 6 months before the first dose of study drug(s).
• •8. Uncontrolled diabetes.